Azacitidine
- PDF / 169,751 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 114 Downloads / 141 Views
1
S
Leucopenia and thrombocytopenia: case report A 6-month-old boy developed leucopenia and thrombocytopenia during treatment with azacitidine for Noonan syndrome (NS)-associated myeloproliferative disorder (MPD) with somatically acquired monosomy-7. The boy, who was diagnosed with NS-associated MPD with somatically acquired monosomy-7, had been previously treated with mercaptopurine [6-mercaptopurine], which was stopped as he developed profound cytopenia, respiratory deterioration and vomiting [aetiologies unknown]. At the age of 6 months, he started receiving azacitidine 25 mg/kg/day [route not stated] for 7/28 days. However, he developed azacitidine-induced leucopenia and thrombocytopenia [duration of treatment to reaction onsets not stated]. He received a total of 6 cycles until the age of 12 months. Additionally, azacitidine was found ineffective. At the age of 3.5 years, he continued to experience fluctuating mild thrombocytopenia, splenomegaly, increased peripheral blood precursor cells and continuously high monosomy-7. No clinical deterioration was noted during a 4-year follow-up period. Author comment: "[S]ix cycles of azacitidine 25 mg/kg/day for 7/28 days were given. These induced. . .leucopenia and thrombocytopenia". Hofmans M, et al. Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7: impact on clinical decision making. British Journal of Haematology 187: E83-E86, No. 4, Nov 2019. Available from: URL: 803439903 http://doi.org/10.1111/bjh.16191 - Belgium
0114-9954/19/1783-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Dec 2019 No. 1783
Data Loading...
